Iovance Biotherapeutics (NASDAQ: IOVA) aims to improve patient care for people living with cancer. Iovance is investigating T cell-based therapies, known as tumor infiltrating lymphocytes (TIL), which use a patient’s own immune cells to attack cancer. Our unique Iovance TIL technology platform has generated novel cell therapies that are currently in clinical studies for multiple cancers. We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida.
Iovance Biotherapeutics
Unlock to Claim this listing
Add / Modify Company
0.42
Overall Excellence Rating
Industry
Pharmaceuticals & BiotechnologyCategory
Biotechnology ResearchESG/Ethical Impact
Iovance Biotherapeutics, as a biotechnology company, demonstrates a commitment to environmental sustainability by integrating responsible practices into its operations. While the primary focus is on developing innovative cancer immunotherapies, the company’s operations and research can also consider environmental stewardship. By implementing energy-efficient lab practices, reducing waste generation, and adopting sustainable sourcing for materials, Iovance Biotherapeutics can minimize its ecological footprint. By implementing energy-efficient lab practices, reducing waste generation, and adopting sustainable sourcing for materials, Iovance Biotherapeutics can minimize its ecological footprint. This showcases a holistic approach to addressing environmental challenges within the biotechnology sector, aligning with broader environmental preservation effortsAligned with its ESG values, Iovance Biotherapeutics recognizes the interconnectedness of responsible practices and sustained financial growth. The company’s integration of sustainability considerations into its financial strategy fosters long-term value creation for patients, partners, and investors. Iovance Biotherapeutics’ approach to risk management, innovation, and strategic investments aligns with its commitment to advancing cancer immunotherapies. By aligning financial success with social responsibility, Iovance Biotherapeutics demonstrates that responsible business practices contribute to both financial performance and positive societal impact. The company’s focus on developing safe and effective immunotherapies while adhering to ethical guidelines underscores its dedication to improving patient health outcomes. Iovance Biotherapeutics’ emphasis on ethical behavior extends to its collaborations with healthcare professionals, regulatory bodies, and stakeholders, ensuring that its therapies positively impact patient care and contribute to the advancement of medical science. Through its ethical excellence, Iovance Biotherapeutics advances its mission of providing ethical and impactful therapeutic solutions while maintaining the highest standards of integrity.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us
Awards Received
2023
Revenues
707000.00
Website Traffic
Employee Rating
3.30
Customer Rating
4.30
Company Size
100-1000
ESG Risk Rating
3.00